Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?

Kochi University

Status: Completed

Conditions: Pancreatic Cancer Metastatic

Treatments: Drug: chemotherapy agents

Study type: Observational

Funder types: Other

Identifiers

NCT06921252

Kochi University

Details and patient eligibility

About

The recurrent pancreatic cancer (Rec-PC) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer. However, the difference between Rec-PC and primary metastatic pancreatic cancer (PM-PC) did not know well. Thus, whether Rec-PC and PM-PC should be included in the same category when conducting clinical trials evaluating chemotherapy remains controversial. The purpose of this study is to investigate the difference of overall survival (OS) between Rec-PC and PM-PC, and analyze their impact on prognosis.

Enrollment: 276 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• unresectable pancreatic cancer

Exclusion criteria

• Patients expected to survive for less than three months

Trial design

276 participants in 2 patient groups

chemotherapy for metastatic pancreatic cancer

Description:

chemotherapy

Treatment:

Drug: chemotherapy agents

chemotherapy for recurrent pancreatic cancer

Description:

postoperative chemotherapy

Treatment:

Drug: chemotherapy agents